(Press-News.org) A breakthrough discovery by the University of East Anglia (UEA) and Children's Hospital Boston promises an effective new treatment for one of the deadliest forms of cancer.
Reporting in the March 24 edition (front cover story) of the journal Nature, the researchers found that leflunomide - a drug commonly used to treat rheumatoid arthritis – also inhibits the growth of malignant melanoma.
Melanoma is a cancer of the pigment cells in our skin. It is the most aggressive form of skin cancer and, unlike most other cancers, incidence of the disease is increasing. More than 10,000 patients in the UK are diagnosed with melanoma each year. If caught early, surgery can be used to safely remove the tumour but the chances of survival for patients whose tumour is already spreading are very low. Around 2000 people a year in the UK die from malignant melanoma because the cancer has returned after being removed surgically.
UEA scientists Dr Grant Wheeler and Dr Matt Tomlinson conducted a rigorous screen of thousands of compounds, looking for those that affect the development of pigment cells in tadpoles. (See: http://www.uea.ac.uk/mac/comm/media/press/2009/jan/tadpoles). They identified a number of compounds that affected pigment cell development and have now shown with their US collaborators at Children's Hospital Boston that leflunomide significantly restricts tumour growth in mouse models.
And when leflunomide is used in combination with PLX4720, a promising new melanoma therapy currently undergoing clinical trials, the effect was even more powerful – leading to almost complete block of tumour growth.
The next stage is for clinical trials to be conducted into the use of leflunomide to fight melanoma. Because leflunomide is already licensed to treat arthritis, this process should be faster than usual and a new treatment for melanoma could be available within around five years.
"This is a really exciting discovery – making use of an existing drug specifically to target melanoma," said Dr Grant Wheeler, of UEA's School of Biological Sciences.
"Deaths from melanoma skin cancer are increasing and there is a desparate need for new, more effective treatments. We are very optimistic that this research will lead to novel treatments for melanoma tumours which, working alongside other therapies, will help to stop them progressing."
The novel work, which was partly funded by the Biotechnology and Biological Sciences Research Council (BBSRC), highlights the strength of carrying out large screens of compounds in developmental model systems such as the Xenopus tadpole used at UEA and the zebrafish used at Childrens Hospital Boston. The hope is that this approach will lead to the discovery of further compounds to treat different diseases in the future.
Lead author Dr Richard White of Children's Hospital Boston and Harvard Medical School, said: "Cancer is a disease not only of genetic mutations, but also one determined by the identity of the cell in which the tumor arises. By studying cancer development in zebrafish and frogs, we gain a unique insight into the very earliest changes that occur in those cells."
INFORMATION:
'Inhibitors of DHODH suppress neural crest development and melanoma growth via modulation of transcriptional elongation' by R White (Children's Hospital Boston), S Ratanasirintrawoot (Children's Hospital Boston), C Lin (MIT), P Rahl (MIT), J Cech (Children's Hospital Boston), C Burke (Children's Hospital Boston), E Langdon (Children's Hospital Boston), M Tomlinson (UEA), J Mosher (University of Michigan), C Kaufman (Children's Hospital Boston), F Chen (Children's Hospital Boston),H Long (Cambridge University), M Kramer (Genzyme Corporation), S Datta (Children's Hospital Boston), D Neuberg (Children's Hospital Boston), S Granter (Children's Hospital Boston), R Young (MIT), S Morrison (University of Michigan), G Wheeler (UEA) and L Zon (Children's Hospital Boston) is published in the March 24 edition of Nature.
END
Brown dwarfs are essentially failed stars: they lack enough mass for gravity to trigger the nuclear reactions that make stars shine. The newly discovered brown dwarf, identified as CFBDSIR 1458+10B, is the dimmer member of a binary brown dwarf system located just 75 light-years from Earth [1].
The powerful X-shooter spectrograph on ESO's Very Large Telescope (VLT) was used to show that the composite object was very cool by brown dwarf standards. "We were very excited to see that this object had such a low temperature, but we couldn't have guessed that it would turn out ...
Smokers of mentholated cigarettes are no more likely to develop lung cancer than other smokers, according to a new, very large, prospective study of black and white smokers published online March 23 in the Journal of the National Cancer Institute. In fact, contrary to a popular hypothesis, menthol smokers in this study had a somewhat lower risk of developing and dying from lung cancer than non-menthol smokers.
Lung cancer rates are higher among blacks than whites, and use of mentholated cigarettes, also higher among blacks, has been suggested as a possible explanation. ...
The latest clues suggesting potential new ways to treat melanoma come from an unlikely source: fish.
Zebrafish don't get sunburns, but they can get skin cancer – at least those fish that have been engineered to model the often deadly human cancer. When Leonard Zon, a Howard Hughes Medical Institute investigator at Children's Hospital Boston, developed this melanoma model five years ago, he hoped to use the tiny striped fish to discover new melanoma genes or new therapies for this aggressive cancer that consistently eludes treatment.
Now, in work described in two papers ...
Scientists have unveiled the most comprehensive picture to date of the full genetic blueprint of multiple myeloma, a form of blood cancer. A study of the genomes from 38 cancer samples has yielded new and unexpected insights into the events that lead to this form of cancer and could influence the direction of multiple myeloma research. This work, led by scientists at the Broad Institute and Dana-Farber Cancer Institute, appears in the March 24 issue of Nature.
Multiple myeloma is the second most common blood cancer in the United States and causes about 20,000 new cases ...
SAN ANTONIO, Texas, U.S.A. (March 24, 2011) — A pill taken once a day in the morning prevented type 2 diabetes in more than 70 percent of individuals whose obesity, ethnicity and other markers put them at highest risk for the disease, U.S. scientists reported today.
The team also noted a 31 percent decrease in the rate of thickening of the carotid artery, the major vessel that supplies blood to the brain. The study, which enrolled 602 participants through The University of Texas Health Science Center San Antonio and seven collaborating centers, is described in the New ...
Scientists who pioneered sequencing the genomes of cancer patients to find novel genetic changes at the root of the disease now have turned their attention to a laboratory workhorse — a mouse.
By sequencing the genome of a mouse with cancer, researchers at Washington University School of Medicine in St. Louis have uncovered mutations that also drive cancer in humans. The investigators are the first to sequence a mouse cancer genome, and their research is reported online March 23 in the Journal of Clinical Investigation.
"This approach gives us a way to rapidly evaluate ...
It is well established that environmental enrichment, providing animals with rich sensory, motor, and social stimulation, produces both dramatic increases in the number of synapses in the brain and enhanced learning. However, causal relationships between synapse formation and improved memory have not been definitively established. Now, a new study published by Cell Press in the March 24 issue of the journal Neuron introduces a valuable model system for investigating the role of synapse turnover in learning and memory in adult animals and elucidates mechanisms that link ...
A new study is providing fascinating insight into how projections conveying sensory information in the brain are guided to their appropriate targets in different species. The research, published by Cell Press in the March 24 issue of the journal Neuron, reveals a surprising new evolutionary scenario that may help to explain how subtle changes in the migration of "guidepost" neurons underlie major differences in brain connectivity between mammals and nonmammalian vertebrates.
The neocortex (the "new" cortex) is a brain area that is unique to mammals and plays a central ...
A detailed analysis of lung tumors that became resistant to targeted therapy drugs has revealed two previously unreported resistance mechanisms. In a report in the March 23 Science Translational Medicine, investigators from the Massachusetts General Hospital (MGH) Cancer Center also describe how the cellular nature of some tumors actually changes in response to treatment and find that resistance-conferring mutations can disappear after treatment is discontinued. The findings support the importance of monitoring the molecular status of tumors throughout the treatment process.
"It ...
Current rules requiring researchers to obtain consent for patients to take part in clinical trials in emergency situations are causing life-threatening delays to treatment, experts have argued.
They say that in severe trauma cases, waiting for a relative to give written permission is "unethical" because of the importance of prompt treatment.
Professor Ian Roberts, Dr Haleema Shakur and Dr David Prieto-Merino, from the Clinical Trials Unit of the London School of Hygiene & Tropical Medicine, make their point in a letter published in The Lancet.
It is co-signed by Sir ...
